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Abstract
Background: Standard chemotherapy protocols in NSCLC are of limited clinical benefit. Histone deacetylase (HDAC)
inhibitors represent a new strategy in human cancer therapy. In this study the combination of the HDAC inhibitor
phenylbutyrate (PB) and the nucleoside analogue gemcitabine (GEM) was evaluated and the mechanisms underlying
increased cell death were analyzed.
Methods: Dose escalation studies evaluating the cytotoxicity of PB (0.01–100 mM), GEM (0.01–100 μg/ml) and a
combination of the two were performed on two NSCLC cell lines (BEN and KNS62). Apoptotic cell death was quantified.
The involvement of caspase-dependent cell death and MAP-kinase activation was analyzed. Additionally, mitochondrial
damage was determined. In an orthotopic animal model the combined effect of PB and GEM on therapy was analyzed.
Results: Applied as a single drug both GEM and PB revealed limited potential to induce apoptosis in KNS62 and Ben
cells. Combination therapy was 50–80% (p = 0.012) more effective than either agent alone. On the caspase level,
combination therapy significantly increased cleavage of the pro-forms compared to single chemotherapy. The broad
spectrum caspase-inhibitor zVAD was able to inhibit caspase cleavage completely, but reduced the frequency of apoptotic
cells only by 30%. Combination therapy significantly increased changes in MTP and the release of cyto-c, AIF and Smac/
Diabolo into the cytoplasm. Furthermore, the inhibitors of apoptosis c-IAP1 and c-IAP2 were downregulated and it was
shown that in combination therapy JNK activation contributed significantly to induction of apoptosis. The size of the
primary tumors growing orthotopically in SCID mice treated for 4 weeks with GEM and PB was significantly reduced
(2.2–2.7 fold) compared to GEM therapy alone. The Ki-67 (KNS62: p = 0.015; Ben: p = 0.093) and topoisomerase IIα
(KNS62: p = 0.008; Ben: p = 0.064) proliferation indices were clearly reduced in tumors treated by combination therapy,
whereas the apoptotic index was comparably low in all groups.
Conclusion:  Therapy combining GEM and the HDAC inhibitor PB initiates a spectrum of apoptosis-inducing
mitochondrial and further JNK-dependent events, thereby overcoming the therapeutic resistance of NSCLC tumor cells.
In vivo, the combination therapy substantially reduced tumor cell proliferation, suggesting that the well tolerated PB is a
useful supplemental therapeutic agent in NSCLC.
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Background
Lung cancer is the leading cause of cancer related death
world wide [1]. Only a minority of patients are suitable
for potentially curative surgical intervention [2]. The
majority of patients are managed with palliative therapy
regimes based primarily on chemotherapy [3]. An increas-
ing number of patients are being treated with neoadjuvant
or adjuvant chemotherapy/radiotherapy based therapeu-
tic strategies [4]. However, the effectiveness of such strate-
gies is still very limited in terms of prolonging survival,
and symptom relief and improving the quality of life
remain the fundamental effects of current regimes [5].
Gemcitabine (GEM) is frequently applied in a combina-
tion therapy regime in patients with advanced lung cancer
[6]. GEM enters the cells via a nucleoside transport system
and is subsequently phosphorylated to inhibit ribonucle-
otide reductase (RNR) and to compete with dCTP for
incorporation into DNA [7]. Like other nucleoside ana-
logues, GEM is able to induce apoptosis in NSCLC cells.
However, the clinical effectiveness in the treatment of
lung cancer is often insignificant, and the major obstacle
is that cancer cells exert substantial resistance towards
chemotherapy induced apoptosis, which considerably
limits the response to therapy [8,9].
Histone deacetylase (HDAC) inhibitors, including phe-
nylbutyrate (PB), induce histone hyperacetylation, which
alters the expression of numerous genes by interfering
with chromatin structure [10]. This is associated with the
induction of apoptosis, differentiation and the inhibition
of proliferation in various solid and hematologic tumors,
including lung cancer [11-13]. However, the clinical ben-
efit of PB treatment alone in advanced malignancies was
limited [14-16], although PB demonstrated a low toxicity
profile. Nevertheless, PB has been FDA-approved for
inborn urea cycle disorders and has a very favorable side-
effect profile.
We recently demonstrated that gemcitabine induces apop-
tosis in lung cancer cell lines by recruiting caspases,
mitogen-activated protein kinases (MAPK) and mito-
chondria triggered (intrinsic) apoptotic signaling [8].
However, the induction of apoptosis was profoundly
blocked in vitro as well as in vivo by the strong apoptotic
resistance of the tumor cells on the level of the mitochon-
dria.
Here we report that PB and GEM in combination have a
potent effect on cytotoxicity in NSCLC cancer cell lines.
The rational for combining these agents was that HDAC
inhibitors had been demonstrated to regulate the expres-
sion of multiple apoptotic mediators and induce mito-
chondria-dependent apoptosis in various malignant
tumor cells, such as melanoma cells, osteosarcoma cells
and leukaemia cells [17-19]. Additionally, Maggio et al.
suggested that MAPK are involved in HDAC inhibitor
induced apoptosis [19]. Here, we show that key events in
mitochondria triggered apoptosis are stimulated by com-
bination therapy, activation of MAPK is enhanced and
inhibitors of apoptosis are down-regulated, resulting in
potent tumor growth inhibition in vitro as well as in vivo
in orthotopic tumor models.
Methods
Cell lines and culture conditions
The human lung cancer cell lines (KNS62 and Ben) have
been described previously [8]. Non-genetically engi-
neered cells were routinely maintained in RMPI 1640 sup-
plemented with 10% FCS, 2 mM glutamine and 1 mM
sodium pyruvate (Life Technologies, Inc., Eggenstein,
Germany) without penicillin or streptomycin. All cells
were kept in a humidified atmosphere containing 5%
CO2 at 37°C.
Immunohistochemical analysis
Resected orthotopically growing tumors were immedi-
ately frozen in liquid nitrogen. Five μm thick frozen tissue
sections were cut from the tumor and fixed for 10 min in
acetone. Immunohistochemical assessment of tumor pro-
liferation was performed by the using monoclonal mouse
antibody MIB-1 (Dianova, Hamburg, Germany) against
the nuclear antigen Ki-67 and the monoclonal mouse
antibody Ki-S4 against topoisomerase IIα (kindly pro-
vided by Prof. Parwaresch, Dept. of Hematopathology
and Lymph Node Registry, Kiel, Germany). Immunolabe-
ling with the specific antibody was evaluated by counting
200 tumor cells in 3 different "hot spots" in each cryosec-
tion at high-power magnification (× 400). Counting was
done by 2 independent observers. The labeling indices
were calculated as percentage of positive tumor cells. The
mean values and standard deviations are based on 3 ani-
mals from each group. From each tumor bearing animal 3
cryosections were taken for analysis.
For staining of intratumoral vascular endothelium, cryo-
sections were stained bwith they monoclonal rat anti-
mouse MEC13.3 (BD Pharmingen, Hamburg, Germany)
against CD31 (PECAM-1). The APAAP method was used
for detection [20]. Microvessel density (MVD) was calcu-
lated according to Weidner et al. [21]. Briefly, areas of ele-
vated vascular density were identified and subsequently
the microvessel entities per optical field (× 200 magnifica-
tion) were counted in 5 different areas of each tumor. Sta-
tistical mean values, SD and p values (t test) were
calculated.
Immunological reagents
Mouse anti-caspase 8 antibodies (clone 5F7) were
obtained from Upstate Biotechnology (Eching, Ger-Journal of Carcinogenesis 2006, 5:25 http://www.carcinogenesis.com/content/5/1/25
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many). Anti-PARP (clone C-2-10) was obtained from Cal-
biochem (Bad Solden, Germany), anti-β-actin (clone AC-
15) from Sigma, and anti-cytochrome c (clone
7H8.2C12) from Pharmingen (Hamburg, Germany).
Rabbit polyclonal antibodies against Bcl-xL were obtained
from Pharmingen, anti-Bid from R&D Systems (Wies-
baden, Germany), anti-caspase 9 from Cell Signaling (Ber-
lin, Germany), antibodies to JNK, phosho-JNK, c-Jun and
phosphor-c-Jun from Cell Signaling. Peroxidase-conju-
gated anti-rabbit IgG and anti-mouse IgG were obtained
from Amersham (Brunswick, Germany). Rabbit polyclo-
nal anti-cIAP1 H-83, and rabbit polyclonal anti-cIAP2 H-
85 antibodies were purchased from Santa Cruz (Heidel-
berg, Germany). Rabbit monoclonal anti-survivin and
anti-XIAP were obtained from Cell Signaling.
Apoptosis assay
The NSCLC cancer cell line KNS 62 was seeded at a density
of 1 × 104 cells/well into 96-well flat-bottom microtiter
plates, allowed to adhere overnight and labeled with 3H-
thymidine (370 kBq/μl; Amersham, Brunswick, Ger-
many) for 3 h. Subsequently, the cells were washed with
phosphate-buffered saline (PBS) and incubated with vari-
ous concentrations of gemcitabine (Lilly), phenylbutyrate
or a combination of the two in normal growth medium
for up to 72 h. The cells were lysed in 0.05% SDS for 30
min at 37°C to ensure complete release of genomic DNA
and harvested by vacuum aspiration on glass-fiber filters.
Dried filters were counted using a liquid scintillation
counter (Wallac, Switzerland). The percentage of specific
DNA fragmentation, indicative of apoptosis, was calcu-
lated as: percentage viability = (E/S) × 100, where E
(experimental) is the counts per minute (cpm) of retained
DNA in the presence of chemotherapy and S (spontane-
ous) is the cpm of retained DNA in the absence of chem-
otherapy [9]. Caspase 3 and caspase 8 activity was
measured by immunoblotting of total cellular proteins
and subsequent detection of caspase 3 and caspase 8 and
cleavage of their substrates PARP and Bid. The broad cas-
pase inhibitor zVAD-fmk was obtained from Biomol, Ltd.
(Hamburg, Germany). The following inhibitors of differ-
ent Mitogen-Activated Protein Kinases (MAPK) were
employed: 1 μmol/L of SP600125 a JNK-specific inhibi-
tor, 10 μmol/L of SB203580 a p38-specific inhibitor and
0.5 μmol/L of MEK1/2-inhibitor, all from Calbiochem
(Bad Soden, Germany).
Cell cycle analysis and apoptosis measurement
The cells were washed twice with PBS, trypsinized, pel-
leted, resuspended in PBS containing 5 mM EDTA and
fixed by adding one volume of ethanol (Merck, Darm-
stadt, Germany). After Rnas -treatment (40 ng RNaseA/μl,
Sigma-Aldrich, Taufkirchen, Germany) cells were pel-
leted, resuspended in PBS containing propidium iodide
(200 μg/ml) and subjected to FACS analysis. Cell cytome-
try was conducted using a FACScan cell analyzer (Becton-
Dickinson Bioscience, San Jose, CA, USA). WinMDI2.8
[22] was used for analyzing FACS data.
Mitochondrial transmembrane potential
Mitochondrial integrity was determined by assessing the
loss of the mitochondrial membrane potential Δψm using
an ApoAlert Mitochondrial Membrane Sensor Kit (Clon-
tech, Heidelberg, Germany) followed by FACScan (Becton
Dickinson) analysis.
Orthotopic transplantation of tumor cells into 
immunodeficient mice
Female SCID-bg (C.B-17/IcrHsd-Prkdcscid  Lystbg) mice
(Harlan Winkelmann, Borchen, Germany) weighing 14 to
19 g were allowed to become acclimatized for 1 week in a
sterile environment where bedding, food and water were
autoclaved. Food and water were given ad libitum. Animal
experiments and care were performed in accordance with
the guidelines of the institutional authorities. The mice
were anaesthetized by i.p. injection of a mixture of Mida-
zolam 5.0 mg/kg (Roche, Grenzach-Wehyen, Germany),
Fentanyl 0.05 mg/kg (Janssen-Cilag, Neuss; Germany)
and Medetomidin 5.0 mg/kg (Pfizer, Karlsruhe, Ger-
many). The orthotopic animal model was performed as
previously published [23]. Briefly, after right lateral thora-
cotomy the lung was carefully exposed and a tumor cell
suspension (1 × 106 cells in 30 μl Matrigel, Biosciences)
was cautiously injected into the lung tissue. The thoracic
wall and the skin were closed with a 6-0 running absorb-
able suture (Ethicon, Norderstedt, Germany). After com-
pletion of the surgical procedure anaesthesia was
antagonized by s.c. injection of a mixture of Flumazenil
0.5 mg/kg (Roche, Grenzach-Wehyen, Germany),
Naloxon 1.2 mg/kg (Curamed, Neuss; Germany) and Ati-
pamezol 2.5 mg/kg (Pfizer, Karlsruhe, Germany). All mice
were inspected daily for complications. Once orthotopic
KNS62 and Ben tumors were established (7 d after ortho-
topic tumor cell injection), the mice were treated with 50
mg/kg GEM i.p. twice a week for 28 days, 300 mg/kg PB
by subcutaneous infusion with Alzet osmotic minipumps
(model 2002; Alzet, Cupertino, CA, USA) or by combina-
tion therapy. The mMinipumps were exchanged after 2
weeks. In the control group NaCl was administered
instead of chemotherapy according to the gemcitabine
scheme. The animals were sacrificed after 35 days and the
tumors were resected. Tumor weight and tumor volume
according to the formula of a rotational ellipsoid (V =
length × height × width × 0.5236) were calculated.
Resected tumors were bisected and cryo- and formalin-
fixed for further investigations. The data were analyzed
using SPSS for Windows (V 11.0, Chicago, IL, USA). The
results are given as means ± SD. Differences in tumor vol-
ume between relevant subgroups were analysed and p val-
ues were calculated by Mann-Whitney U test. A global pJournal of Carcinogenesis 2006, 5:25 http://www.carcinogenesis.com/content/5/1/25
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value of less then 0.05 was considered to be statistically
significant.
Results
Sensitivity of lung cancer cells to GEM and PB mediated 
apoptosis
We analyzed the sensitivity of two different NSCLC cell
lines (KNS62 and Ben) to increasing doses of GEM and
PB. The cell lines underwent apoptosis in a dose-depend-
ent manner, showing fragmentation of cellular DNA,
though KNS62 was less sensitive than Ben to GEM and PB
(Fig. 1, upper and middle panel). When GEM and PB were
combined, either in high dosage (10 μg/ml GEM and 5
mM PB) or in low dosage (1 μg/ml GEM and 2 mM PB),
the rate of viable cells was significantly decreased com-
pared to single substance treatment. Remarkably, an effect
exceeding the sum of single agent treatment was detecta-
ble in the KNS62 low dosage treatment group (Fig. 1,
lower panel).
Effect of GEM and PB combination treatment on 
apoptotic cell death
Various indicators of apoptotic cell death were investi-
gated in KNS62 and Ben cells after treatment with GEM
and PB in combination. PI-FACS analyses of the PI-
stained cells focused especially on the sub-G1 cellular
DNA fraction. The combination treatment revealed a sig-
nificant increase in DNA in the sub-G1 fraction compared
to gemcitabine treatment alone (Fig. 2, upper panel).
After 72 h of combination therapy 46% of KNS62 cells
and 54% of Ben cells were detectable in the sub-G1 cellu-
lar (apoptotic) fraction, compared to only 19% of KNS62
and 24% of Ben after treatment with gemcitabine alone.
To quantify the early apoptotic phenotype Annexin-V/PI-
FACS analyses were performed (Fig. 2, lower panel). As
early apoptotic events Annexin-V-positive cells (right
lower quadrant in the density dot plot) as well as PI-posi-
tive and Annexin-V-positive cells (right upper quadrant)
were summarized. After combination therapy signifi-
cantly more cells revealed early morphologic events of
apoptosis (KNS62: 34%; Ben: 39%) than cells treated with
gemcitabine alone (KNS62: 11%; Ben: 14%).
Activation of caspases by combined chemotherapy
The activation of key apoptotic proteins was investigated
to evaluate the influence of GEM, PB and combination
chemotherapy on apoptosis at the molecular level. In
death receptor-mediated apoptosis, receptor activation is
followed by cleavage of caspase-8 and its substrate BID, a
BH3 domain-containing pro-apoptotic protein that sub-
sequently becomes activated. Cleavage of caspase-8 and
Bid was low in KNS62 cells after GEM and PB treatment
alone, but significantly increased with combination ther-
apy (Fig. 3a). Similarly, cells subjected to combination
therapy exhibited clearly increased cleavage of caspase-9
in KNS62.
The dependence of chemotherapy-induced cell death on
caspase-mediated apoptotic pathways was confirmed by
the observation that the broad caspase-inhibitor zVAD
prevented apoptosis-related DNA fragmentation and
PARP cleavage in treated cells (Fig. 3b+c). However, DNA
fragmentation was only partially inhibited, suggesting fur-
ther mechanisms besides caspase-dependent apoptosis.
Mitochondrial integrity after combined chemotherapy
The involvement of mitochondria in chemotherapy-
mediated apoptosis was determined by assessing mito-
chondrial integrity. After 24 h of combination chemother-
apy only 11% of KNS62 cells exhibited a loss of Δψm,
compared to 7% in the gemcitabine group and 8% in the
DNA fragmentation of NSCLC cells by chemotherapy Figure 1
DNA fragmentation of NSCLC cells by chemother-
apy. A. Dose-response curves for the NSCLC cell lines 
KNS62 and Ben towards gemcitabine (GEM); (upper panel) 
and phenylbutyrate (PB); (lower panel). Quantification of cel-
lular DNA fragmentation by the JAM assay in lung carcinoma 
cells treated with different concentrations as indicated. B. 
DNA fragmentation by combination PB/GEM therapy with 
two different concentrations of combined chemotherapy. 
100% viability = untreated control.
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Specification of apoptotic cell death induced by chemotherapy Figure 2
Specification of apoptotic cell death induced by chemotherapy. A. Quantification of apoptotic cells by PI-FACS cell 
cycle analysis for combined chemotherapy in KNS62 and Ben lung cancer cell lines. B. Quantification of apoptosis by Annexin-
V/PI-FACS analyses. PI: FL2-H; Annexin: FL1-HJournal of Carcinogenesis 2006, 5:25 http://www.carcinogenesis.com/content/5/1/25
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phenylbutyrate group. This difference increased over time
from 29% (48 h) and 44% (72 h) of cells with defective
Δψm in the combination group compared with 12%/16%
(48/72 h) for gemcitabine and 14%/19% (48/72 h) for
phenylbutyrate (Fig. 4a).
These results were confirmed by the demonstration of
cytochrome-c, Smac/Diabolo and AIF release from mito-
chondria into the cytosol, as detected by Western blot
analyses of cytosolic proteins. In the cytosolic fractions of
combination chemotherapy-exposed KNS62 cells there
was a significantly higher release of cytochrome-c, Smac/
Diabolo and AIF into the cytosole compared to single
agent (gemcitabine or phenylbutyrate) therapy (Fig. 4b).
An analysis of protein expression levels of various family
members of the inhibitors of apoptosis proteins (IAP)
revealed that especially c-IAP1 and c-IAP2 were signifi-
cantly down regulated by PB and combination therapy,
whereas XIAP remained stable and survivin showed only
moderate regulation (Fig. 4c).
JNK regulates combination chemotherapy induced 
apoptosis
Since mitogen-activated protein kinases (MAPK) have
been determined to be substantially involved in control-
ling chemotherapy-induced apoptosis [24,25], we investi-
gated the involvement of MAPK in GEM and PB
combination therapy-induced apoptosis. While treatment
of KNS62 with either GEM or PB induces phosphorylation
of ERK1/2, p38, JNK and its target c-Jun, combination
therapy amplifies this effect substantially (Figure 5a). The
overall level of these proteins (ERK1/2, p38, JNK and c-
Jun) remaiedn unchanged (data not shown). The impact
of activation of different MAP-Kinases on apoptosis was
tested by co-incubation of specific inhibitors. Only spe-
cific blocking of p-JNK significantly inhibited the induc-
tion of apoptosis by chemotherapy (Figure 5b), whereas
the level of phosphorylated c-Jun as the target of activated
JNK was effectively decreased by the JNK inhibitor
SP600125 (Fig. 5c).
Orthotopic growth of NSCLC tumors in SCID mice treated 
with GEM and PB chemotherapy
The effect of gemcitabine and phenylbutyrate on in vivo
tumor growth was investigated in an orthotopic SCID
mouse model. Each group comprised six animals. In
untreated animals, KNS62 the mean tumor size was 110
mm3 (SD: 32.6) compared to 92.5 mm3 (SD: 42.2) in the
GEM group, 79.3 mm3 (SD: 37.0) in the PB group and
33.8 mm3 (SD: 24.3) in the combination group. The
tumor size was significantly smaller in the combination
group compared to GEM (p = 0.008) or PB (p = 0.028)
chemotherapy alone (Fig. 6a).
In orthotopically growing Ben tumors the mean tumor
size in the untreated group was 95 mm3 (SD: 30), in the
GEM group 36.6 mm3 (SD: 21.6), in the PB group 29.7
mm3 (SD: 18.8) and in the combination therapy group
16.2 mm3  (SD: 10.3). Like in the KNS62 orthotopic
model in the Ben tumors were significantly smaller in the
combination therapy group compared to GEM (p =
0.035) and PB (p = 0.026) (Fig. 6a).
The analysis of the proliferation activity of orthotopically
growing tumors by means of Ki-67 and topoisomerase IIα
staining indices revealed significant inhibition of prolifer-
Caspase-dependent apoptotic cell death Figure 3
Caspase-dependent apoptotic cell death. Caspase acti-
vation in the lung cancer cell line KNS62 by combination 
chemotherapy. A. Detection of caspase-8, Bid, caspase-9 and 
PARP cleavage in KNS62 after the indicated treatment. B. 
Inhibition of apoptosis by broad caspase inhibitor zVAD after 
corresponding treatment. C. Inhibition of PARP cleavage 
zVAD after treatment.
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Involvement of MAPK activation in chemotherapy induced  apoptosis Figure 5
Involvement of MAPK activation in chemotherapy 
induced apoptosis. A. Phosphorylation of the MAPK mem-
bers ERK1/2, JNK and its target c-Jun and p38 by the indi-
cated treatment. B. Inhibition of apoptosis by the JNK 
inhibitor SP600125. C. Inhibition of phosphorylation of c-Jun 
by JNK-inhibitor.
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Chemotherapy induced changes in mitochondrial stability Figure 4
Chemotherapy induced changes in mitochondrial 
stability. A. Measurement of the loss of Δψm in KNS62 
treated with indicated chemotherapy at different time points. 
Effect of combination chemotherapy on mitochondrial func-
tion. B. Detection of cytochrome-c, Smac/Diabolo and AIF 
release into the cytoplasma after 48 h of therapy. C. Expres-
sion levels of the IAP members XIAP, c-IAP1, c-IAP2 and sur-
vivin after 48 h of treatment.
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Inhibition of in vivo tumor growth by chemotherapy Figure 6
Inhibition of in vivo tumor growth by chemotherapy. A. Tumor volume of orthotopically growing KNS62 and Ben 
tumours treated with gemcitabine, phenylbutyrate or combination chemotherapy for 4 weeks. B. Ki-67 labeling indices of 
orthotopically growing tumors. C. Topoisomerase IIα labeling indices of orthotopically growing tumors.
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ation in both combination therapy groups (KI-67:
KNS62: GEM = 25.7% vs. combi = 15.3%; Ben: GEM =
18.2% vs. combi = 13.8%; topoisomerase IIα: KNS62:
GEM= 34.7% vs. combi = 17.3%; Ben: GEM = 27% vs.
combi = 19%) compared to untreated animals or animals
with single agent therapy (Fig. 6b+c).
The rate of apoptotic cells (staining of cytokeratin 18 frag-
ments with M30 antibody and phosphorylation of his-
tone H2B with anti p-H2B) was only slightly elevated
(data not shown). The microvessel density (MVD; anti-
CD31 positivity) was also only slightly lower in the com-
bination group (data not shown).
Discussion
NSCLC is still associated with a very poor prognosis, and
the effectiveness of current chemotherapy protocols is still
very limited in terms of prolonging survival [5]. However,
new strategies, such as the inhibition of deacetylation of
histones, have been developed to overcome the resistance
of tumor cells to chemotherapy. Acetylation of histones
induces changes in the chromatin structure and increases
the accessibility of the DNA, leading to gene activation.
On the other hand deacetylation by histone deacetylase
(HDAC) inactivates gene expression. This was specified as
epigenetic modification of gene expression [26]. Such a
strategy might address deregulated genes in lung cancer
tumor tissue that are responsible for tumor progression
and therapy resistance [27].
A few studies have demonstrated anti-tumoral effects of
various HDAC inhibtors even in phase II clinical trials,
although the effectiveness as single agent therapy was lim-
ited and our understanding of the underlying mecha-
nisms remain superficial [28].
The HDAC inhibitor PB belongs to the family of short
fatty acids and is used for treatment of inborn defects of
the urea cycle without major side effects [29]. The dosages
administered in the animal models in this study were
comparable to those applied in the clinical setting; there-
fore PB qualifies for a rapid transfer to clinical testing. We
demonstrated that PB effectively increased GEM induced
apoptosis in NSCLC cell cancer cell lines both in vitro and
in vivo. In this context several studies have demonstrated
in NSCLC that especially resistance to intrinsic pathway
mediated apoptosis is associated with strong resistance to
chemotherapy, especially on the level of ineffective cas-
pase activation [8,9]. This is in line with other studies
showing that in leukemia, prostate cancer and colon can-
cer the combination of conventional chemotherapy with
HDAC inhibitors was able to enhance the effectiveness of
therapy substantially [12,30-32].
Several authors have identified numerous differentially
expressed genes in NSCLC compared to normal tissue that
might be relevant for apoptotic resistance to chemother-
apy[33,34]. We investigated the activation of several cen-
tral apoptosis regulators, such as caspase-8 and its
substrate Bid, caspase-9 and caspase-3, along with crucial
biochemical parameters such as mitochondrial integrity
and release of cytochrome-c, Smac/Diabolo and AIF into
the cytoplasm. By employing PB, we addressed the aber-
rant expression of various genes simultaneously and not
only the expression of one or few specific genes. Whereby
apoptosis controlling pathways might be reactivated [29].
In this context we were able to show that combination
therapy substantially increased the activation of the above
mentioned key players in apoptotic cell death compared
to single agent chemotherapy. Especially the blockage of
these key activators contributes to chemotherapy resist-
ance in lung cancer [35]. Therefore, the pro-apoptotic sig-
naling of the HDAC inhibitor PB and GEM converge and
substantially improve the impact on tumor growth sup-
pression.
In the context of enhanced mitochondria triggered cell
death due to disrupted mitochondrial transmembrane
potential we detected the release of cytochrome-c, AIF and
Smac/Diabolo into the cytoplasm, decreased levels of
anti-apoptotoc c-IAP1 and c-IAP2 but unchanged levels of
XIAP. These results are in accordance with the results of
Yang at al. 2004, who identified Smac/Diabolo as a key
molecule for selectively reducing protein levels of c-IAPs
and in this way contributing to enhanced apoptosis.
Noteworthy in this regard is the release of the caspase-
independent cell death effector AIF into the cytoplasm,
which likely helps to explain why in this study combined
chemotherapy induced apotosis was partially inhibited by
the broad spectrum caspase-inhibitor zVAD. This is sup-
ported by several studies showing that AIF significantly
contributes to caspase-independent cell death [36,37].
Our further analysis of the PB-mediated sensitizing effects
demonstrated that PB significantly enhanced the gemcit-
abine-mediated activation of JNK. Inhibition of JNK activ-
ity by the JNK inhibitor SB600125 partially reduced
chemotherapy-mediated apoptosis. This finding is in line
with a recent study demonstrating the relevance of the
JNK pathway for in vitro apoptosis induction due to single
drug PB treatment in lung carcinoma cells [24]. In our
model system inhibition of the JNK pathway particularly
decreased the gemcitabine dependent cell death.
The in vitro results suggest that apoptosis is the predomi-
nant mechanism for increasing tumor cell sensitivity
towards gemcitabine and phenylbutyrate combination
chemotherapy. However, in in vivo tumors analyzed in theJournal of Carcinogenesis 2006, 5:25 http://www.carcinogenesis.com/content/5/1/25
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combination group the rate of apoptotic cells (staining of
cytokeratin 18 fragments with M30 antibody and phos-
phorylation of histone H2B with anti p-H2B) was only
slightly elevated (data not shown). This might be
explained by the long treatment period, during which the
majority of the apoptotic cells were already eliminated.
The microvessel density (MVD; anti-CD31 positivity) was
also only slightly lower in the combination group. How-
ever, suppression of angiogenesis by HDAC inhibitors
might have an impact on tumor growth inhibition, as pre-
viously demonstrated in a prostate cancer model [38]. In
the in vivo model the main effects on combination therapy
were evident on the level of significantly reduced cell pro-
liferation, as demonstrated by strongly reduced staining
indices for KI-67 and topoisomerase IIα.
Conclusion
In summary, these results demonstrate that the combina-
tion of gemcitabine and the HDAC inhibitor phenylbu-
tyrate is an effective treatment regime for NSCLC by
improved activation of caspase-dependent, mitochondria
transmembrane stability mediated and JNK-activated
apoptotic cell death. These in vitro findings together with
two clinically relevant tumor model systems provide
strong evidence that the well tolerated drug PB might be a
promising supplemental therapeutic agent for the treat-
ment of NSCLC and should be further evaluated in a clin-
ical setting.
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